How I'd Invest $10,000 Right Now

The author recommends allocating $10,000 across SCHD ($5,000), Verizon ($3,000) and Viking Therapeutics ($2,000) to balance income, stability and growth amid rising rates, high valuations and political uncertainty. SCHD yields 3.2% versus just under 1.1% for the S&P 500 and has risen close to 30% this year; Verizon yields 6.3%, has an 11x P/E and a roughly 72% payout ratio. Viking is the higher-risk position: its $3.3 billion market cap and promising VK2735 trial results offer upside, but approval is not assured.

Analysis

The proposed mix is less defensive than its framing: SCHD and Verizon remain equities exposed to higher real yields, and the ETF may already hold Verizon, so the allocation can duplicate rather than diversify telecom exposure. A continued rise in Treasury yields could pressure both the fund’s valuation and Verizon’s income-stock appeal; Verizon’s debt and ongoing network investment also make the dividend less bond-like than the yield suggests. Verify current SCHD holdings and Verizon’s free-cash-flow coverage before sizing that overlap.

For Verizon, the near-term risk from SpaceX’s direct-to-device service is more likely incremental competition in coverage gaps and roaming than immediate replacement of mainstream mobile service. The longer-term threat depends on spectrum access, service quality, device compatibility, and carrier partnerships. A regulatory or commercial launch milestone would matter more than speculative headlines; competitive pricing or weaker subscriber trends would be a more direct thesis-breaker.

VKTX is an event-driven development asset, not a dependable growth sleeve. Maintenance-dose data may differentiate the candidate, but approval, durability of efficacy, safety, manufacturing scale, and payer access remain separate hurdles. Eli Lilly benefits from category growth, yet could face eventual share or pricing pressure if credible alternatives emerge. Treat a buyout as optionality, not underwriting. The contrarian point: a high dividend and a promising trial do not together make an income portfolio low-risk. In the next 1–3 months, verify trial/regulatory milestones and updated cash-flow data; over 6–18 months, outcomes and commercialization capacity dominate VKTX’s value.

Key Decisions for Investors

• Do not treat the 80% SCHD/VZ allocation as cash-like capital. If adding exposure, stage SCHD rather than chase a sharp run-up, and check fund holdings to avoid unintended VZ concentration. Reassess if real yields continue higher or Verizon’s free-cash-flow dividend coverage weakens.
• Keep VZ as an income-equity position only while subscriber trends, churn, and free cash flow support the payout. Monitor SpaceX service and spectrum/regulatory milestones; a demonstrable shift in customer retention or pricing—not launch headlines alone—would falsify the near-term limited-threat view.
• Size VKTX as a capped, speculative catalyst position; do not assign value to a presumed acquisition. Before adding, confirm the next clinical and regulatory milestones, comparative efficacy/safety versus Eli Lilly’s offerings, and funding runway. A negative trial update or materially weaker differentiation is a reason to cut risk.
• There is no compelling evidence here for a forced trade. Prefer a diversified core with a measured dividend tilt; avoid using VKTX to offset rate sensitivity, since biotech event risk and rate-driven equity risk can both hurt simultaneously.